Cargando…

P63 BREAKTHROUGH COVID-19 IN FULL VACCINATED PATIENTS WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE OF 54 PATIENTS

Detalles Bibliográficos
Autores principales:	Sgherza, N., Curci, P., Rizzi, R., Perfetto, A., Battisti, O., Pizzileo, N., De Trizio, G., Musto, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Poster
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171796/ http://dx.doi.org/10.1097/01.HS9.0000936380.75760.2b

Ejemplares similares

P-159: Effectiveness of anti-SARS-CoV-2 vaccine “booster” dose in patients with multiple myeloma
por: Sgherza, Nicola, et al.
Publicado: (2022)

P29: EFFECTS OF VACCINATION ON INCIDENCE AND OUTCOME OF SARS-COV-2 INFECTION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS)
por: Sgherza, N, et al.
Publicado: (2022)

Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma
por: Sgherza, Nicola, et al.
Publicado: (2021)

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021)

P948: INCIDENCE AND CLINICAL OUTCOME OF SARS-COV-2 INFECTION AFTER VACCINATION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS)
por: Sgherza, N., et al.
Publicado: (2022)

SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma
por: Sgherza, Nicola, et al.
Publicado: (2021)

What Is New in the Treatment of Smoldering Multiple Myeloma?
por: Bolli, Niccolo’, et al.
Publicado: (2021)

P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY
por: Spiliopoulou, V., et al.
Publicado: (2023)

P55 MULTIPLE MYELOMA AND SARS-COV-2 INFECTION: AN EUROPEAN HEMATOLOGY ASSOCIATION SURVEY (EPICOVIDEHA) OF 1,221 PATIENTS THROUGH THE DIFFERENT PHASES OF COVID-19 PANDEMIC
por: Musto, P., et al.
Publicado: (2023)

Humoral Immune Response after anti-SARS-CoV-2 Vaccine “Booster” Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)
por: Sgherza, Nicola, et al.
Publicado: (2023)

P18: DARATUMUMAB (D) PLUS BORTEZOMIB (V) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE”
por: Mele, G, et al.
Publicado: (2022)

P17: DARATUMUMAB (D) PLUS LENALIDOMIDE (R) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY-RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE”
por: Mele, G, et al.
Publicado: (2022)

P1598: SARS-COV2 INFECTION IN FULLY VACCINATED PATIENTS WITH LYMPHOID MALIGNANCIES DURING THE “THIRD WAVE”: A SINGLE-CENTER EXPERIENCE OF 57 PATIENTS.
por: Strafella, V., et al.
Publicado: (2022)

SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance
por: Sgherza, Nicola, et al.
Publicado: (2022)

575. Local Experience of Breakthrough SARS-CoV-2 Infections After Full Vaccination
por: Khan, Ahmed A, et al.
Publicado: (2021)

PB2016: COMPARISON BETWEEN DRD VS KRD AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS IN FIRST RELAPSE: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP)
por: Mele, A., et al.
Publicado: (2022)

P03: RATIONALE AND DEVELOPMENT OF AN E-HEALTH APPLICATION TO DELIVER PATIENT CENTERED CARE DURING TREATMENT FOR MULTIPLE MYELOMA IN THE NETHERLANDS.
por: Geerts, P, et al.
Publicado: (2022)

63: A MICROBIOLOGICAL RETROSPECTIVE REVIEW OF BLOOD STREAM INFECTIONS IN COVID-19 PATIENTS FROM A TERTIARY CARE CENTER IN LEBANON
por: Nahhal, S., et al.
Publicado: (2022)

Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study
por: Sgherza, Nicola, et al.
Publicado: (2021)

COVID-19 in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): An Observational Retrospective Study
por: Sgherza, Nicola, et al.
Publicado: (2021)

Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies
por: Chien, Kelly S., et al.
Publicado: (2022)

Identification of signalling pathways downstream of BRCA1 and p63
por: Crawford, N, et al.
Publicado: (2010)

63. Frequency and Outcomes of Patients Prescribed Antibiotics for Extended Durations on Discharge from the Hospital to Nursing Homes
por: Molina, Kaitlyn E, et al.
Publicado: (2020)

P932: ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY
por: Mina, R., et al.
Publicado: (2022)

P928: REAL-LIFE ANALYSIS OF THE MULTIPLE MYELOMA PATIENT’S SURVIVAL IN A LARGE COHORT OF PATIENTS
por: Lopez-Muñoz, N., et al.
Publicado: (2022)

P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY
por: Rodríguez-Otero, P, et al.
Publicado: (2022)

Cytogenetic and interphase Fluorescence in Situ Hybridization studies in patients with multiple myeloma
por: Perumal, G, et al.
Publicado: (2014)

P917: HOW COMORBID ARE OUR MYELOMA PATIENTS AND HOW MANY MAKE IT TO THE SECOND-LINE TREATMENT: REAL-WORLD DATA OF 251 MYELOMA PATIENTS TREATED IN THE HEMATOLOGICAL NETWORK OF THE OEGK
por: Keil, F., et al.
Publicado: (2022)

P33 EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL-LIFE SETTING: THE ALFA STUDY
por: Roussel, M., et al.
Publicado: (2023)

P-143: Breakthrough – a designated pharmacist in the hemato-oncology department improves both quality and sequence of drug treatment and reduces ADR in Multiple Myeloma patients during Covid-19 pandemic
por: Alabbasi, Areen, et al.
Publicado: (2021)

P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL
por: Larocca, A., et al.
Publicado: (2023)

P852: NEOANTIGENS PREDICTED BY THE GNE NEOANTIGEN PIPELINE IN PATIENTS DIAGNOSED WITH DE NOVO MULTIPLE MYELOMA
por: Jiang, Y., et al.
Publicado: (2022)

P1585: THE ROLE OF INTESTINAL MICROBIOME IN SYSTEMIC INFECTIONS IN PATIENTS WITH MULTIPLE MYELOMA
por: Burylev, V., et al.
Publicado: (2022)

Endoscopic resection of colloid cyst: long-term followup with 63 patients
por: Isaacs, Albert, et al.
Publicado: (2015)

Feasibility of an individual surveillance program on contamination with direct measurement methods based on the criteria established in the ICRP publication 54
por: Melandri, C, et al.
Publicado: (1990)

P58 LOW CD38 EXPRESSION BY PLASMA CELLS IN EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS
por: Notarfranchi, L., et al.
Publicado: (2023)

1150. Breakthrough Invasive Fungal Disease (IFD) in Patients with Acute Myeloid Leukemia (AML)
por: Wasylyshyn, Anastasia, et al.
Publicado: (2020)

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
por: Barbui, Tiziano, et al.
Publicado: (2022)

P08 TEMPORAL TRENDS IN PROGNOSIS OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA (SMM) WHO MEET CRITERIA FOR BIOMARKER-DEFINED EARLY MULTIPLE MYELOMA (SLIM CRAB POSITIVE MM)
por: Ludwig, H., et al.
Publicado: (2023)

P927: CLINICAL CHARACTERISTICS, SURVIVAL OUTCOMES AND PROGNOSIS IN 123 IMMUNOGLOBULIN D MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE SINGLE-CENTER
por: Liu, J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h6v92hd7c2v3gq56gknaq13m21